Abstract

The aim of the present research is to discuss the effect of carboprost tromethamine plus oxytocin on the efficacy, safety and blood loss of patients with placenta previa and hemorrhage. 118 individuals with placenta previa and hemorrhage from December 2018 to December 2022 were selected, and were divided into control group and research group. Control group received routine treatment plus oxytocin, while research group were additionally given carboprost tromethamine on the basis of the treatment used for control group. The curative effect, safety (chills, dizziness, nausea and vomiting), blood loss (intraoperative and 2 h postoperative blood loss), recovery (hemostasis time, operation time and length of stay), serum inflammatory indices (tumor necrosis factor-alpha, interleukin-6 and white blood cells count) were comparatively analyzed. After analysis, research group was found to have a higher total treatment effective rate, a lower incidence of adverse events, and less blood loss intraoperatively and 2 h postoperatively; in addition, shorter hemostasis time, operation time and length of stay were determined in research group. All the above differences were statistically significant, while the two groups showed similar levels of serum inflammatory indicators. The combination of carboprost tromethamine and oxytocin is effective and safe for the treatment of patients with placenta previa and hemorrhage, which can validly reduce the amount of bleeding during and 2 h after surgery, speed up hemostasis, and promote patient recovery.